AUA BPH
Provides evidence‑based recommendations for evaluating and treating lower urinary tract symptoms caused by benign prostatic hyperplasia.
Indications for Use
Used for men ≥45 with bothersome LUTS attributed to BPH after excluding other causes; guides evaluation, need for medical therapy, and thresholds for referral or surgery. Clinical utility is to standardize symptom scoring (IPSS), identify candidates for α‑blockers or 5‑ARIs, and determine when complications (retention, infections, stones, hematuria, renal insufficiency) warrant surgical management (AUA Guideline 1).
Insights & Cautions
Start with symptom scoring and objective measures (IPSS, prostate size, flow rate), but avoid overreliance because these tools do not predict progression or treatment response well (AUA Guideline 2021 1 [Level I evidence]). Key cautions: limited validation across diverse populations; no ability to estimate risk of acute urinary retention or incidental cancer; and should not substitute for clinical assessment, urinalysis, or shared decision-making.